Literature DB >> 18307370

Antiretroviral therapy : pharmacokinetic considerations in patients with renal or hepatic impairment.

Sarah M McCabe1, Qing Ma, Judianne C Slish, Linda M Catanzaro, Neha Sheth, Robert DiCenzo, Gene D Morse.   

Abstract

Hepatic and renal insufficiency due to co-infection, alcoholism, diabetes mellitus, family history, adverse effects of antiretrovirals and other factors are commonly seen in HIV-infected patients. Therefore, the use of antiretrovirals in this patient setting requires attention to the pharmacokinetic issues that clinicians must consider when prescribing highly active antiretroviral therapy for these patients. This review summarizes the current knowledge of the use of antiretrovirals in patients with hepatic or renal impairment, and makes dosing recommendations for this subpopulation of HIV-infected patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18307370     DOI: 10.2165/00003088-200847030-00002

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  114 in total

1.  Pharmacokinetics of single-dose oral stavudine in subjects with renal impairment and in subjects requiring hemodialysis.

Authors:  D M Grasela; R R Stoltz; M Barry; M Bone; B Mangold; P O'Grady; R Raymond; S J Haworth
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

Review 2.  Therapeutic drug monitoring in HIV treatment: a literature review.

Authors:  Benjamin Z Wertheimer; Kenneth A Freedberg; Rochelle P Walensky; Yazdan Yazdanapah; Elena Losina
Journal:  HIV Clin Trials       Date:  2006 Mar-Apr

3.  Tipranavir: a protease inhibitor for multi-drug resistant HIV-1.

Authors:  Brookie Best; Richard Haubrich
Journal:  Expert Opin Investig Drugs       Date:  2006-01       Impact factor: 6.206

Review 4.  Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors.

Authors:  Antonio Rivero; José A Mira; Juan A Pineda
Journal:  J Antimicrob Chemother       Date:  2007-01-25       Impact factor: 5.790

Review 5.  Update on the pharmacokinetic aspects of antiretroviral agents: implications in therapeutic drug monitoring.

Authors:  J C Slish; L M Catanzaro; Q Ma; O O Okusanya; L Demeter; M Albrecht; G D Morse
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

6.  Severe efavirenz-induced hypersensitivity syndrome (not-DRESS) with acute renal failure.

Authors:  Alfonso Angel-Moreno-Maroto; Laura Suárez-Castellano; Michele Hernández-Cabrera; Jose-Luis Pérez-Arellano
Journal:  J Infect       Date:  2005-07-05       Impact factor: 6.072

7.  Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients.

Authors:  J P Dieleman; I C Gyssens; M E van der Ende; S de Marie; D M Burger
Journal:  AIDS       Date:  1999-03-11       Impact factor: 4.177

8.  Acute interstitial nephritis associated with atazanavir, a new protease inhibitor.

Authors:  Ursula C Brewster; Mark A Perazella
Journal:  Am J Kidney Dis       Date:  2004-11       Impact factor: 8.860

9.  Pharmacokinetics of zidovudine in patients with liver cirrhosis.

Authors:  A M Taburet; S Naveau; G Zorza; J N Colin; J F Delfraissy; J C Chaput; E Singlas
Journal:  Clin Pharmacol Ther       Date:  1990-06       Impact factor: 6.875

10.  Didanosine pharmacokinetics in patients with normal and impaired renal function: influence of hemodialysis.

Authors:  E Singlas; A M Taburet; F Borsa Lebas; O Parent de Curzon; A Sobel; P Chauveau; B Viron; R al Khayat; J L Poignet; F Mignon
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

View more
  9 in total

1.  Development and validation of an assay to analyze atazanavir in human hair via liquid chromatography/tandem mass spectrometry.

Authors:  Nhi Phung; Karen Kuncze; Hideaki Okochi; Alexander Louie; Leslie Z Benet; Igho Ofokotun; David W Haas; Judith S Currier; Tariro D Chawana; Anandi N Sheth; Peter Bacchetti; Monica Gandhi; Howard Horng
Journal:  Rapid Commun Mass Spectrom       Date:  2018-03-15       Impact factor: 2.419

2.  Dosing nucleoside reverse transcriptase inhibitors in adults receiving continuous veno-venous hemofiltration.

Authors:  Milena M McLaughlin; Abeer T Ammar; Lana Gerzenshtein; Kimberly K Scarsi
Journal:  Clin Drug Investig       Date:  2015-04       Impact factor: 2.859

3.  Evaluation of nucleoside reverse transcriptase inhibitor dosing during continuous veno-venous hemofiltration.

Authors:  Milena M McLaughlin; Inela Masic; Lana Gerzenshtein
Journal:  Int J Clin Pharm       Date:  2016-11-25

Review 4.  Novel Antiretroviral Drugs in Patients with Renal Impairment: Clinical and Pharmacokinetic Considerations.

Authors:  Dario Cattaneo; Cristina Gervasoni
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-08       Impact factor: 2.441

5.  Zidovudine and Lamivudine for HIV Infection.

Authors:  Peter L Anderson; Joseph E Rower
Journal:  Clin Med Rev Ther       Date:  2010

6.  Pharmacokinetics and safety of boosted elvitegravir in subjects with hepatic impairment.

Authors:  Joseph M Custodio; Martin Rhee; Gong Shen; Kah Hiing J Ling; Brian P Kearney; Srinivasan Ramanathan
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

Review 7.  Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.

Authors:  Roger K Verbeeck
Journal:  Eur J Clin Pharmacol       Date:  2008-09-02       Impact factor: 2.953

8.  Relevance of Liver Failure for Anti-Infective Agents: From Pharmacokinetic Alterations to Dosage Adjustments.

Authors:  Fiona V Bϋdingen; Daniel Gonzalez; Amelia N Tucker; Hartmut Derendorf
Journal:  Ther Adv Infect Dis       Date:  2014-02-01

9.  Long-term treatment of patients with HIV-1: the role of atazanavir.

Authors:  Miguel Ángel Artacho; Pablo Barreiro; José Vicente Fernández-Montero
Journal:  HIV AIDS (Auckl)       Date:  2010-09-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.